Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 14.33 -0.10 (-0.69%) Official Closing Price Updated: 7:00 PM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Takeda Pharmaceutical Ltd ADR < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders March 19, 2024 From Centogene NV Via GlobeNewswire Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia March 13, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire The Hot List: 3 AI Stocks Worth Buying on Weakness March 01, 2024 Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Looking Into Takeda Pharmaceutical's Recent Short Interest January 15, 2024 Via Benzinga (TAK) - Analyzing Takeda Pharmaceutical's Short Interest December 25, 2023 Via Benzinga (TAK) - Analyzing Takeda Pharmaceutical's Short Interest December 07, 2023 Via Benzinga Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas February 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus February 12, 2024 Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies. Via Benzinga Exposures Product Safety FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE) February 12, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study February 09, 2024 Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024. Via Benzinga Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024 February 08, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Why Is Japanese Drugmaker Takeda Stock Trading Lower Today? February 01, 2024 Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated. Via Benzinga Takeda Announces Chief Financial Officer Succession February 01, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Earnings Scheduled For February 1, 2024 February 01, 2024 Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... Via Benzinga Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products February 01, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) January 29, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) January 29, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire 3 Stocks to Buy to Benefit From the Booming Sleep Industry January 23, 2024 It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation. Via InvestorPlace Takeda Named Global Top Employer for Seventh Consecutive Year January 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Time to buy these 3 healthcare companies that raised revenue guidance? January 16, 2024 The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance. Via MarketBeat U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) January 16, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week January 13, 2024 Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will... Via Talk Markets More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 January 04, 2024 More than 140 brands of drugs are going to see their prices hiked heading into the new year Via Talk Markets Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January December 29, 2023 Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on... Via Benzinga One Ultra-Cheap High-Yield Dividend Stock to Buy December 22, 2023 Now may be a good time for dividend investors to consider loading up on this stock. Via The Motley Fool Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies December 21, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach December 19, 2023 Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,... Via Benzinga Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) December 15, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners December 05, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases November 27, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.